Company

Chai Discovery

AI-driven drug discovery company building foundation models for protein structure prediction and antibody sequence design to accelerate drug development

Healthcare & BiotechAI

People

Joshua Meierfounder, co-founder

Funding History

Jul 14, 2026

Chai Discovery raised $400M at a $3.8B valuation, with Index Ventures, Kleiner Perkins, Sequoia Capital, and Dimension Capital as lead investors.

400M

Investors

Index VenturesKleiner PerkinsSequoia CapitalDimension CapitalNeo

News

Interviews (2)

Chai Discovery raises $400M at $3.8B valuation to bring AI-designed drug molecules to Eli Lilly, Novartis, and Pfizer
14 Jul 2026
Chai Discovery launches CHI-2, an antibody foundation model achieving 15-20% success rates and potentially eliminating high-throughput lab screening
30 Jun 2025